News
Trial results, approvals, pricing changes, safety findings and market moves across peptides and GLP-1 medications — each traced to a primary source, each dated. For enforcement actions specifically, see the regulatory tracker.
- Trial results
- Approvals
- Pricing changes
- Safety findings
-
225 self-harm reports across three GLP-1 drugs, and what the comparison can and cannot show
Read more: 225 self-harm reports across three GLP-1 drugs, and what the comparison can and cannot showBetween January 2021 and December 2025, Europe’s pharmacovigilance database logged 42,941 adverse-event reports naming liraglutide, semaglutide or tirzepatide as a suspect drug in diabetes or weight management. Of those, 225 involved suicide or self-injury: 141 for semaglutide, 47 for tirzepatide, 37 for liraglutide. A new analysis sets the three against each other and finds such…
-
Why GLP-1 weight loss varies so much: 32 trials, 40,408 people
Read more: Why GLP-1 weight loss varies so much: 32 trials, 40,408 peopleA meta-analysis of 32 randomised trials covering 40,408 people puts the average weight loss on GLP-1 and dual-agonist drugs at 9.36%. Most of the paper is about why that average hides so much. Trials enrolling people who also had type 2 diabetes, obstructive sleep apnoea or fatty liver disease reported systematically smaller losses. Trials that…
-
Tirzepatide and semaglutide carried the same asthma risk in 16,352 patients
Read more: Tirzepatide and semaglutide carried the same asthma risk in 16,352 patientsAmong adults who have both asthma and type 2 diabetes, starting tirzepatide rather than semaglutide made no difference to the chance of an asthma attack over a year. A US multicentre analysis of 16,352 matched patients, published on 7 September 2026, found that 11.0% of the tirzepatide group and 11.1% of the semaglutide group had…
-
An expert panel maps out how to use the first two MASH drugs
Read more: An expert panel maps out how to use the first two MASH drugsFor most of the time this site has covered semaglutide, the scarring form of fatty liver disease had no approved drug treatment at all. That has changed. An international expert panel writing in Gut on 11 September 2026 has published a clinical practice update for the two therapies now conditionally approved by the FDA for…
-
GLP-1 drugs left bone alone but lean mass fell, a 60-study review finds
Read more: GLP-1 drugs left bone alone but lean mass fell, a 60-study review findsA meta-analysis of 60 studies and more than 1.25 million people, published in Drugs on 12 September 2026, gives the fullest picture yet of what GLP-1 drugs do to muscle, bone and joints. The bone finding is reassuring: no measurable effect on bone mineral density, and none on fractures. The muscle finding is the one…
-
GLP-1 drugs took off another 9% after bariatric surgery, a 27-study review finds
Read more: GLP-1 drugs took off another 9% after bariatric surgery, a 27-study review findsBetween a quarter and a third of people who have bariatric surgery regain a significant amount of weight within two to five years, according to the figures cited by the authors of a new review. Their meta-analysis, published in Frontiers in Endocrinology, pulls together what is known about treating that regain with a GLP-1 drug…
-
378 trials ranked: incretin drugs top the list for preventing type 2 diabetes
Read more: 378 trials ranked: incretin drugs top the list for preventing type 2 diabetesA network meta-analysis of 378 randomised trials covering 113,122 adults with prediabetes has ranked what actually prevents type 2 diabetes, and incretin drugs finished first: dual GLP-1/GIP receptor agonists cut the risk of developing diabetes by around 90% against control, and single GLP-1 receptor agonists by around 74%. Metformin plus intensive lifestyle change came third.…
-
80% of adolescents on GLP-1 drugs still had food in the stomach after 13 hours of fasting
Read more: 80% of adolescents on GLP-1 drugs still had food in the stomach after 13 hours of fastingEighty per cent of adolescents taking a GLP-1 receptor agonist still had solid food in the stomach when they arrived for a procedure, despite having fasted for a median of 13 hours, well beyond the eight hours standard guidelines ask for. Among healthy adolescents fasting under the same instruction, the figure was 5%. The study,…
-
Two in five children on semaglutide fell below the obesity threshold at 68 weeks
Read more: Two in five children on semaglutide fell below the obesity threshold at 68 weeksNovo Nordisk reported on 7 September that 40.4% of children aged 6 to under 12 who took once-weekly semaglutide in its STEP Young trial were no longer classified as having obesity after 68 weeks, compared with none of the children given placebo. Every child in both arms also followed a reduced-calorie diet and an exercise…
-
SGLT2 drugs edged out GLP-1s on atrial fibrillation in 216,000 adults
Read more: SGLT2 drugs edged out GLP-1s on atrial fibrillation in 216,000 adultsAmong 216,293 adults with type 2 diabetes, starting an SGLT2 inhibitor was associated with a lower five-year risk of atrial fibrillation than starting a GLP-1 receptor agonist: 4.3% against 4.8%. Starting both classes together came in at 4.2%, statistically indistinguishable from SGLT2 alone. For anyone weighing the two classes with an eye on heart rhythm…